A new drug being tested in patients with advanced melanoma, the most dangerous form of skin cancer, has shown significant antitumor activity, according to preliminary results of a new study. The research, conducted by a team of experts from UCLA's Jonsson Comprehensive Cancer Center, led by Dr. Antoni Ribas, professor of medicine in the division of hematology-oncology, demonstrated that the novel drug comes with "very manageable side effects...
Monday 3 June 2013
Subscribe to:
Post Comments (Atom)
0 comments:
Post a Comment